Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety.

Abstract

ATV treatment of HIV-infected patients with or without a RTV booster was safe and effective in clinical routine. Drug levels were sufficient in the majority of cases. The variability of pharmacokinetic results in our sample supports therapeutic drug monitoring in patients treated with ATV.